Pyrithioxin dihydrochloride
Based on 2 publication(s) in Google Scholar
Pyrithioxin (Pyritinol) dihydrochloride is the dihydrochloride salt of Pyrithioxin (HY-B0910). Pyrithioxin (Pyritinol) is an orally active neurodynamic compound. Pyrithioxin can promote the metabolism of glucose and amino acids, increase carotid blood flow and improve cerebral blood flow. Pyrithioxin exhibits anti-inflammation, anti-tumor and neuroprotective effect. Pyrithioxin can be used for the researches of cancer, inflammation, immunology, metabolic and neurological disease such as cerebral infarct, epilepsy, fibrosarcomas and rheumatoid polyarthritis.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 10049-83-9
- Formula: C16H22Cl2N2O4S2
- Molecular Weight:441.39
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-COVID-19 Compound Library
HY-L052
-
Glycolysis Compound Library
HY-L058
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Animal-Sourced Natural Product Library
HY-L157
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Vitamin Compound Library
HY-L197
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
Natural Product Diversity Scaffold Library
HY-L245
Publications Citing Use of MedChemExpress (MCE) Pyrithioxin dihydrochloride
More
Biological Activity
|
Human Endogenous Metabolite |
Pyrithioxin dihydrochloride (0.5-3 μg/mL) increases D-arabitol production from Candida parapsilosis by regulating glucose-6-phosphate dehydrogenase[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pyrithioxin (200 and 600 mg/kg diet, added to the feed for free consumption, 6 weeks) elevates acetylcholine levels and enhances memory behavior in rats[4].
Pyrithioxin (50-200 mg/kg, p.o.) reduces flinching behavior in Streptozocin (HY-13753)-induced diabetic rats[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WISTAR rats with 3-MC-induced subcutaneous fibrosarcomas[2]
-
Dosage:20 mg/kg
-
Administration:Orally gavage, five times a week after tumor appearance or after tumor resection
-
Result:Showed remission rate 11%-12%.
Partial recurrence control was achieved in remitted rats with small tumors (0.7-1 cm in diameter) under continuous administration.
Chemical Information
-
CAS No. 10049-83-9
-
Appearance Solid
-
Molecular Weight 441.39
-
Formula C16H22Cl2N2O4S2
-
Color White to off-white
-
SMILES
OCC1=C(CSSCC2=C(CO)C(O)=C(C)N=C2)C=NC(C)=C1O.[H]Cl.[H]Cl
-
Synonyms
Pyritinol dihydrochloride; Pyridoxine disulfide dihydrochloride; Vitamin B6 disulfide dihydrochloride
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
INSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis. [Abstract]2026 Mar 15;17(1):4002. PMID: 41833955 -
Int J Biol Macromol
Unveiling the mechanistic link between peroxiredoxin inhibition and ferroptosis-like cell death induced by Dinaciclib in Entamoeba histolytica. [Abstract]2026 Mar:350:150992. PMID: 41713546
Solvent & Solubility
DMSO : 66.67 mg/mL (151.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (113.28 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (113.28 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Stoica E, et al. Facilitation through hyperventilation of therapeutic effect of pyrithioxin in cerebral infarct patients. Eur Neurol. 1975;13(4):285-303. [Content Brief]
[2]. von Metzler A. et al. [Antineoplastic activity of drugs affecting the central nervous system against chemically induced tumors in the rat (author's transl)]. J Cancer Res Clin Oncol. 1979 Sep;95(1):11-8. German. [Content Brief]
[3]. Crouzet J, et al. Pyrithioxine et polyarthrite rhumatoïde [Pyrithioxin and rheumatoid polyarthritis]. Rev Rhum Mal Osteoartic. 1986 Jan;53(1):45-8. [Content Brief]
[4]. Marston HM, et al. Effects of the chronic administration of pyrithioxin on behaviour and cholinergic function in young and aged rats. J Psychopharmacol. 1987 Jan;1(4):237-43. [Content Brief]
[5]. Zheng S, et al. Combined mutagenesis and metabolic regulation to enhance D-arabitol production from Candida parapsilosis. J Ind Microbiol Biotechnol. 2020 May;47(4-5):425-435. [Content Brief]
[6]. Martínez-Lage JM, et al. Asociación de piritioxina y difenilhidantoina, en el tratamiento de los síndromes epilépticos orgánicos [Association of pyrithioxin and diphenylhydantoin in the treatment of organic epileptic syndromes]. Med Clin (Barc). 1965 Sep;45(3):204-5. [Content Brief]
[7]. Jiménez-Andrade GY, et al. Pyritinol reduces nociception and oxidative stress in diabetic rats. Eur J Pharmacol. 2008 Aug 20;590(1-3):170-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.2656 mL | 11.3279 mL | 22.6557 mL | 56.6393 mL |
| 5 mM | 0.4531 mL | 2.2656 mL | 4.5311 mL | 11.3279 mL | |
| 10 mM | 0.2266 mL | 1.1328 mL | 2.2656 mL | 5.6639 mL | |
| 15 mM | 0.1510 mL | 0.7552 mL | 1.5104 mL | 3.7760 mL | |
| 20 mM | 0.1133 mL | 0.5664 mL | 1.1328 mL | 2.8320 mL | |
| 25 mM | 0.0906 mL | 0.4531 mL | 0.9062 mL | 2.2656 mL | |
| 30 mM | 0.0755 mL | 0.3776 mL | 0.7552 mL | 1.8880 mL | |
| 40 mM | 0.0566 mL | 0.2832 mL | 0.5664 mL | 1.4160 mL | |
| 50 mM | 0.0453 mL | 0.2266 mL | 0.4531 mL | 1.1328 mL | |
| 60 mM | 0.0378 mL | 0.1888 mL | 0.3776 mL | 0.9440 mL | |
| 80 mM | 0.0283 mL | 0.1416 mL | 0.2832 mL | 0.7080 mL | |
| 100 mM | 0.0227 mL | 0.1133 mL | 0.2266 mL | 0.5664 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz